The overall response rate of this revolutionary cancer therapy named FUCASO is 96%. The NMPA’s approval marks a turning point in China’s fight against multiple myeloma. This blog explores the effectiveness of this therapy, its safety, and its potential to improve patient outcomes. Dive in and learn more about FUCASO and the hope it brings for refractory Meelo badan bukaanka.
Multiple myeloma, a kansarka dhiigga that affects plasma cells, can be a daunting opponent. It reduces immunity, and weakens bones, and, in spite of advances, it is still difficult to find long-term remedies. Multiple myeloma is estimated to affect approximately 176,404 people worldwide in 2020.
Multiple myeloma is the second most prevalent type of blood cancer, after qanjiro, yet it is still considered rare. It is more common in elderly people, with the average age of diagnosis being about 70. But there’s a ray of hope with advanced Daaweynta unugyada CAR T ee Shiinaha.
Maamulka Alaabada Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa dhawaan ansixiyay BCMA cusub CAR T daawaynta unugyada kansarka ee Shiinaha oo loo yaqaan FUCASO, taasoo calaamad u ah isbeddelka suurtagalka ah ee dagaalka lagula jiro cudurkan adag. Marka, waa maxay myeloma badan, maxayse FUCASO u abuuraysaa farxad noocaas ah?
Daraasadihii ugu dambeeyay waxay muujinayaan ballanqaad cajiib ah inta lagu jiro tijaabooyinka, iyadoo guud ahaan heerka jawaab celinta ee 96% iyo heerka jawaab celinta dhamaystiran ee 74.3% lagu arkay 103 bukaan oo diiwaangashan. Blog-gani wuxuu si qoto dheer u galayaa sayniska ka dambeeya FUCASO, saameynta ay ku yeelan karto bukaannada myeloma, iyo rajada ay u keenayso dagaalka caalamiga ah ee ka dhanka ah cudurkan adag.
Kharashka badan ee la xidhiidha daawaynta kansarku miyay kugu dareensiinaysaa in aad dareento culayska fikirka xun?
Looma baahnid inaad wax badan ka walwasho! Kaliya halkan guji oo soo ogow daawaynta kansarka bilaashka ah ee Shiinaha taasi waxay rajo cusub gelisay bukaanada aduunka oo dhan.
Waa maxay Cudurka Myeloma Multiple?
Multiple myeloma, oo inta badan loo yaqaanno unugyada plasma myeloma ama kaliya myeloma, waa kansar unugyada balaasmaha, kuwaas oo ah unugyada dhiiga cad ee laga helo dhuuxa lafta. Unugyada Plasma waxay guud ahaan soo saaraan unugyada difaaca jirka, kuwaas oo ah borotiinno ka caawiya jidhkaaga inuu la dagaallamo caabuqyada.
Unugyada Plasma ee ku jira dhowr myeloma waxay u koraan si aan caadi ahayn waxayna u tarmaan si aan la xakamayn karin. Unugyadan balaasmaha ah ee aan caadiga ahayn waxay ururiyaan unugyada dhiigga ee caafimaadka qaba ee dhuuxa lafta, taasoo keentay inay soo saaraan borotiinno M aan caadi ahayn.
Soo ogow Calaamadaha: Tilmaamaha War-bixineed ee Calaamadaha xiiqsan iyo Calaamadaha Myeloma Badan
Saamaynta Multiple Myeloma ee Jirka Aadanaha:
Dhaawaca lafaha: borotiinnada M iyo unugyada balaasmaha ee aan caadiga ahayn waxay dhaawici karaan unugyada lafaha, taasoo keenta xanuunka, jabka, iyo lafo-beelka.
Dhibaatooyinka kelyaha: borotiinnada M waxay ku ururi karaan kelyaha waxayna wiiqi karaan shaqadooda.
Dhiig-yaraan: Culayska ka soo baxa unugyada dhiigga ee caafimaadka qaba ee unugyada balaasmaha ee aan caadiga ahayn waxay keeni kartaa dhiig-yaraan, taasoo keenta daal iyo neefsasho.
Difaaca daciifka ah: Unugyada balasmaha ee aan caadiga ahayn ma awoodaan inay abuuraan unugyada difaaca jirka ee caadiga ah, taas oo jidhka ka dhigaysa mid u nugul caabuqyada.
Halkan ka akhri: Sidee Baadhista Cilad-sheegashadu u Badbaadinaysaa Nolosha Dagaalka Myeloma ee Badan?
Sayniska Ka Danbaysa FUCASO Daaweynta Myeloma Badan Ee Shiinaha
FUCASO (Equecabtagene Autoleucel) waxay la mid tahay daawaynta kansarka kakan ee loo yaqaanno multiple myeloma, gaar ahaan dadka uu kansarku soo noqday ka dib daawayntii hore (dib-u-soo-noqoshada ama refractory multiple myeloma, RRMM).
Daawayntan gaarka ah waxay isticmaashaa awooda habka difaaca qofka si uu ula dagaalamo kansarka si shakhsiyeysan oo daweyn kara. Daawayntan, unugyada T-da waxa lagu beddelaa reseptors gaar ah oo loo yaqaan CARs (Chimeric Antigen Reseptors), iyaga oo ka dhigaya sida gantaallada la hagayo kuwaas oo aqoonsan kara oo weerari kara bartilmaameedyada gaarka ah ee unugyada kansarka. FUCASO daaweynta myeloma badan ee Shiinaha waa mid gaar ah dhowr sababood oo muhiim ah:
Bini-aadminimo buuxda: Si ka duwan daawaynta la midka ah, FUCASO waxay isticmaashaa qaybaha aadanaha oo dhan, taas oo ka dhigaysa mid aad u yar inay keento diidmo iyo waxyeelo.
BCMA-Specific: CAR ee FUCASO waxay si gaar ah u bartilmaameedsanaysaa BCMA, borotiinka si aad ah ugu jira unugyada myeloma. Saxnimadani waxay yaraynaysaa xadiga dhaawaca soo gaadhay unugyada caafimaadka qaba.
Lentivirus As A Gene Vector: Tani waa hab aad wax ku ool u ah gaarsiinta hiddo-wadaha unugyada T. Waxay u ogolaataa T lymphocytes inay aqoonsadaan oo ay burburiyaan unugyada myeloma.
Awood leh oo joogto ah: FUCASO si weyn ayaa loo tijaabiyay waxaana lagu ogaaday inay aad waxtar u leedahay oo ay sii socoto bukaanada qaba myeloma badan, taas oo rajo ka siinaysa cafis waqti dheer ah.
Maamulka Alaabada Caafimaadka Qaranka ee Shiinaha (NMPA) ayaa dhawaan siisay iftiinka cagaaran ee FUCASO® si loogu isticmaalo daawaynta myeloma badan. Waad ku mahadsan tahay dadaalka Innovent Biologics iyo IASO Bio, daawayntan superhero u eg hadda waa la heli karaa, taasoo calaamad u ah tallaabo weyn oo hore loogu qaaday dagaalka ka dhanka ah cudurkan adag. Daawayntan cusubi waxay keenaysaa iftiin cusub oo rajo mustaqbal ifaya leh.
Sidoo kale akhri: Immunotherapy waxay kaa caawin kartaa inaad ku guulaysato dagaalka ka dhanka ah Multiple Myeloma!
Maxaa Dhacay Intii lagu jiray Tijaabada Daaweynta FUCASO ee Multiple Myeloma ee Shiinaha?
The FUMANBA-1 tijaabada caafimaadka, conducted in China, examined the efficacy and safety of FUCASO (Equecabtagene Autoleucel) in patients with relapsed or refractory multiple myeloma (RRMM). The trial included 103 patients who each got a single dose of FUCASO, a CAR-T cell therapy for cancer in China.
Natiijooyinka daraasaddan bukaan-socodyadu waxay ahaayeen kuwo cajiib ah:
Heerka jawaabta sare: 96% bukaanada ayaa ka jawaabay daawaynta, iyadoo 74.3% ay heleen jawaab celin dhamaystiran oo daran (sCR) ama jawaab dhamaystiran (CR), taas oo macnaheedu yahay inaysan jirin unugyo kansar oo la aqoonsan karo.
Jawaab degdeg ah: Waqtiga dhexdhexaadka ah ee jawaab celinta waxay ahayd 16 maalmood oo keliya, taasoo muujinaysa saameyn degdeg ah cudurka.
Cafisyada waara: 12 bilood, 78.8% bukaannadu wali waxay ahaayeen horumar la'aan, taasoo muujinaysa waxtarka daawaynta ee muddada dheer.
Cafis qotodheer: 95% bukaanada ayaa helay cudurka ugu yar ee haraaga ah (MRD), taas oo macnaheedu yahay inay jiraan unugyo kansar oo aad u yar oo aan la ogaan karin.
Wax ku ool u ah bukaanada sida aadka ah loo daweeyay: Xataa bukaanada helay daawaynta CAR-T ka hor si fiican ayay uga jawaabeen, iyagoo 9 gaadhay CR iyo 5 gaadheen sCR.
Positive safety profile: Only a few individuals encountered minor side effects such as cytokine sii daayo syndrome or neurotoxicity, and they all recovered well.
Joogteynta daaweynta: Bilaha 12 iyo 24, unugyada FUCASO ayaa lagu ogaan karaa qayb weyn oo bukaanno ah, taas oo muujinaysa suurtogalnimada ficil dheer.
Xogtan, oo lagu soo bandhigay kulanka Bulshada Maraykanka ee Oncology Clinical ee 2023, waxay tilmaamaysaa ballanqaadka FUCASO inuu yahay daaweyn aad u guul leh oo si wanaagsan loo dulqaatay.
Waa maxay Kharashka daawaynta FUCASO ee Multiple Myeloma ee Shiinaha?
Qiimaha daawaynta FUCASO ee myeloma badan ee Shiinaha waa ku dhawaad $160,000 USD. Iyadoo ay taasi u muuqan karto lacag aad u badan, waxaa muhiim ah in la ogaado in daawayntani tahay tallaabo muhiim ah oo hore loo qaaday oo lagu caawinayo dadka qaba myeloma badan.
Waxay ku siinaysaa fursad natiijooyin horumarsan iyo nolol wanaagsan. Haddii aad ka fekereyso daawayntan, waa fikrad wanaagsan inaad la tashato takhaatiirtaada ama nala soo xiriir si aad u hesho kaalmo dhaqaale haddii aadan awoodin inaad bixiso kharashka daaweynta.
Lacagta ku baxday tan cusub Daaweynta unugyada CAR T in China is not just about paying for the treatment – it’s an investment in a new and better way to fight against multiple myeloma.
Isbitaalada ugu Fiican ee loogu talagalay daawaynta FUCASO ee Multiple Myeloma ee Shiinaha
Aan kaa caawino inaad ogaato qaar ka mid ah kuwa ugu fiican isbitaalada Shiinaha oo bixiya FUCASO daaweynta myeloma badan.
Isbitaalka Kansarka ee Jaamacadda Peking
Cisbitaalka Kansarka ee Jaamacadda Peking waa machad caan ah oo loo arko mid ka mid ah tas-hiilaadka daaweynta kansarka ee ugu wanaagsan Shiinaha. Waxay ku taal cidhifka ugu sarreeya ee hal-abuurka caafimaadka, had iyo jeer riixaya xuduudaha cilmi-baarista kansarka, ogaanshaha, iyo daaweynta.
Waxaa xusid mudan, Cisbitaalka Kansarka ee Jaamacadda Peking waa hormuudka daawaynta unugga CAR T, isagoo siinaya doorashadan daawaynta casriga ah ee bukaannada wajahaya kansarro kala duwan, oo ay ku jiraan myeloma badan.
Markaa, haddii aad ka fiirsanayso daawaynta unugga CAR T ee myeloma badan, cusbitaalku shaki la'aan waa machad sumcad leh oo mudan in la baadho.
Isbitaalka Shanghai Changzheng
Cisbitaalka Changzheng, oo ku yaala wadnaha Shanghai, waa tusaale ifaya oo heer sare ah caafimaad, oo bixiya daawaynta heer-goyn sida daaweynta unugyada CAR T ee kansarka dhiigga ee kala duwan, oo ay ku jiraan myeloma badan.
Isbitaalka Changzheng ee Waaxda Dhiigbaxa ayaa hogaamisa barnaamijka daawaynta unug ee CAR T, iyada oo adeegsanaysa sannadaha khibradeeda iyo qalabkeeda sare si ay u bixiso barnaamijyo daawaynta shakhsi ahaaneed.
Kooxdooda gaarka ah ee dhakhaatiirta dhiiga, dhakhaatiirta kansarka, iyo kalkaaliyayaasha ayaa si wadajir ah u shaqeeya si loo hubiyo in bukaan kasta uu helo daryeelka ugu tayada sarreeya inta lagu jiro safarka daaweynta.
Isbitaalka Lu-Daopei
Dr. Lu Daopei, oo ah dhakhtar caan ah oo ku takhasusay cudurrada dhiigga, ayaa aasaasay Isbitaalka Lu-Daopei, kaas oo isu taagay inuu hormuud ka noqdo daaweynta cudurrada dhiigga iyo cilmi-baarista Shiinaha. Waxaa xusid mudan, inay khibrad la taaban karo u leeyihiin daawaynta unugga CAR-T, iyagoo bixinaya beddelkan kacaanka ah ee bukaannada la dagaallamaya myeloma badan iyo kansarro kale.
They were the first in China to use CAR-T cells to treat B-cell Lymphoblastic lymphoblastic leukemia (B-ALL) and have since performed over 300 successful CAR-T procedures for various blood cancers.
Beijing Gobroad Boren Hospital
Qaybta dhiigbaxa ee Cisbitaalka Gobroad Boren ee Beijing waxay ku takhasustay wax ka qabashada xanuunada dhiigbaxa iyada oo in ka badan soddon sano oo waayo-aragnimo ah u leh goobaha caafimaadka gudaha iyo shaybaadhka.
Waaxdu waxay bixisa adeegyo baaritaan iyo daawaynta oo dhamaystiran oo kala duwan sida myeloma-ka badan, leukemia, lymphoma, thalassaemia, dhibaatooyinka xinjirowga, iyo burooyinka hematological.
Marka ay timaado xulashooyinka daawaynta, waxay bixiyaan daawayn balaadhan oo loogu talagalay burooyinka dhiiga, oo ay ku jiraan: kemotherabi, immunotherapy, daawaynta la beegsaday, iyo radiotherapy.
La xidhiidh KansarkaFax si aad u hesho Caawinaad La Xidhiidha Daaweynta Myeloma
Haddii adiga ama qof aad jeceshahay aad la tacaalayso myeloma badan, CancerFax ayaa halkan u joogta inay ku caawiso. Waxaan la mid nahay saaxiib saaxiib ah oo jidkaaga caafimaadka horumaray.
CancerFax waxay la shaqaysaa cosbitaalada kansarka ee aduunka oo dhan, oo ay ku jiraan MD Anderson, Memorial Sloan Kettering, iyo Mayo Clinic, si ay u caawiyaan bukaanada doonaya fikrado labaad ama daryeel gaar ah inay helaan daawaynta casriga ah.
Tobankii sano ee la soo dhaafay, waxaan caawinaynay dad ka kala yimid in ka badan 8 wadan, anaguna diyaar ayaan u nahay inaan ku taageerno. Nala soo xidhiidh maanta si aad u sahamiso ikhtiyaarada daawaynta unug ee CAR T ee ugu fiican Shiinaha oo aad u bilowdo jidkaaga si aad u dareento fiicnaan.
